Influenza: prospect for prevention and control.
Identifieur interne : 000341 ( PubMed/Corpus ); précédent : 000340; suivant : 000342Influenza: prospect for prevention and control.
Auteurs : Jason R. Williams ; Po-Yen Chen ; Cheng T. Cho ; Tom D Y. ChinSource :
- The Kaohsiung journal of medical sciences [ 1607-551X ] ; 2002.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Disease Outbreaks, Humans, Influenza A virus (isolation & purification), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Vaccines, DNA (immunology), Vaccines, Inactivated (immunology).
- MESH :
- chemical , immunology : Influenza Vaccines, Vaccines, DNA, Vaccines, Inactivated.
- chemical , therapeutic use : Antiviral Agents.
- epidemiology : Influenza, Human.
- isolation & purification : Influenza A virus.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Disease Outbreaks, Humans.
Abstract
Influenza is an emerging and re-emerging disease. Since the late 1930s influenza viruses have been isolated yearly from different parts of the world during epidemics and pandemics. The "epidemiologic success" of influenza is due largely to rapid and unpredictable antigenic changes (antigenic drift) among human influenza viruses, and the emergence of new subtypes (antigenic shift), mostly from reassortment between human and avian influenza viruses. Antigenic shifts were attributed to the global pandemic viruses of 1957 (H2N2 Asian flu) and 1968 (H3N2 Hong Kong flu). Concern over possible new pandemics has been heightened by recent reports of human infection in Asia in 1997 with avian viruses (H5N1) and in 1999 (H9N2) and isolation of human-avian reassorted viruses from pigs and humans in Europe. Influenza has a high rate of inapparent infection, short incubation and high infectivity; epidemics usually start abruptly and spread rapidly to neighboring communities and countries. Isolation and quarantine are often unsuccessful in preventing the spread of the infection. Although not perfect, immunization and chemoprophylaxis are highly effective at minimizing the spread of influenza and reducing morbidity and mortality, social disruption and economic loss. Plans for future influenza epidemics and pandemics require national and international programs to be in place for the monitoring of influenza activity, the dissemination and exchange of information and the provision and delivery of sufficient quantities of vaccines and antiviral agents. This paper reviews and discusses the antigenic variations of the influenza virus, potential influenza pandemics, protective efficacy of inactivated vaccines and antiviral agents and preparation for control of future epidemics and pandemics.
PubMed: 12515400
Links to Exploration step
pubmed:12515400Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza: prospect for prevention and control.</title>
<author><name sortKey="Williams, Jason R" sort="Williams, Jason R" uniqKey="Williams J" first="Jason R" last="Williams">Jason R. Williams</name>
<affiliation><nlm:affiliation>Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Po Yen" sort="Chen, Po Yen" uniqKey="Chen P" first="Po-Yen" last="Chen">Po-Yen Chen</name>
</author>
<author><name sortKey="Cho, Cheng T" sort="Cho, Cheng T" uniqKey="Cho C" first="Cheng T" last="Cho">Cheng T. Cho</name>
</author>
<author><name sortKey="Chin, Tom D Y" sort="Chin, Tom D Y" uniqKey="Chin T" first="Tom D Y" last="Chin">Tom D Y. Chin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12515400</idno>
<idno type="pmid">12515400</idno>
<idno type="wicri:Area/PubMed/Corpus">000341</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000341</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza: prospect for prevention and control.</title>
<author><name sortKey="Williams, Jason R" sort="Williams, Jason R" uniqKey="Williams J" first="Jason R" last="Williams">Jason R. Williams</name>
<affiliation><nlm:affiliation>Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Po Yen" sort="Chen, Po Yen" uniqKey="Chen P" first="Po-Yen" last="Chen">Po-Yen Chen</name>
</author>
<author><name sortKey="Cho, Cheng T" sort="Cho, Cheng T" uniqKey="Cho C" first="Cheng T" last="Cho">Cheng T. Cho</name>
</author>
<author><name sortKey="Chin, Tom D Y" sort="Chin, Tom D Y" uniqKey="Chin T" first="Tom D Y" last="Chin">Tom D Y. Chin</name>
</author>
</analytic>
<series><title level="j">The Kaohsiung journal of medical sciences</title>
<idno type="ISSN">1607-551X</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Disease Outbreaks</term>
<term>Humans</term>
<term>Influenza A virus (isolation & purification)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Vaccines, DNA (immunology)</term>
<term>Vaccines, Inactivated (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, DNA</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Outbreaks</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza is an emerging and re-emerging disease. Since the late 1930s influenza viruses have been isolated yearly from different parts of the world during epidemics and pandemics. The "epidemiologic success" of influenza is due largely to rapid and unpredictable antigenic changes (antigenic drift) among human influenza viruses, and the emergence of new subtypes (antigenic shift), mostly from reassortment between human and avian influenza viruses. Antigenic shifts were attributed to the global pandemic viruses of 1957 (H2N2 Asian flu) and 1968 (H3N2 Hong Kong flu). Concern over possible new pandemics has been heightened by recent reports of human infection in Asia in 1997 with avian viruses (H5N1) and in 1999 (H9N2) and isolation of human-avian reassorted viruses from pigs and humans in Europe. Influenza has a high rate of inapparent infection, short incubation and high infectivity; epidemics usually start abruptly and spread rapidly to neighboring communities and countries. Isolation and quarantine are often unsuccessful in preventing the spread of the infection. Although not perfect, immunization and chemoprophylaxis are highly effective at minimizing the spread of influenza and reducing morbidity and mortality, social disruption and economic loss. Plans for future influenza epidemics and pandemics require national and international programs to be in place for the monitoring of influenza activity, the dissemination and exchange of information and the provision and delivery of sufficient quantities of vaccines and antiviral agents. This paper reviews and discusses the antigenic variations of the influenza virus, potential influenza pandemics, protective efficacy of inactivated vaccines and antiviral agents and preparation for control of future epidemics and pandemics.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12515400</PMID>
<DateCompleted><Year>2003</Year>
<Month>02</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>09</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1607-551X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>9</Issue>
<PubDate><Year>2002</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The Kaohsiung journal of medical sciences</Title>
<ISOAbbreviation>Kaohsiung J. Med. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Influenza: prospect for prevention and control.</ArticleTitle>
<Pagination><MedlinePgn>421-34</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Influenza is an emerging and re-emerging disease. Since the late 1930s influenza viruses have been isolated yearly from different parts of the world during epidemics and pandemics. The "epidemiologic success" of influenza is due largely to rapid and unpredictable antigenic changes (antigenic drift) among human influenza viruses, and the emergence of new subtypes (antigenic shift), mostly from reassortment between human and avian influenza viruses. Antigenic shifts were attributed to the global pandemic viruses of 1957 (H2N2 Asian flu) and 1968 (H3N2 Hong Kong flu). Concern over possible new pandemics has been heightened by recent reports of human infection in Asia in 1997 with avian viruses (H5N1) and in 1999 (H9N2) and isolation of human-avian reassorted viruses from pigs and humans in Europe. Influenza has a high rate of inapparent infection, short incubation and high infectivity; epidemics usually start abruptly and spread rapidly to neighboring communities and countries. Isolation and quarantine are often unsuccessful in preventing the spread of the infection. Although not perfect, immunization and chemoprophylaxis are highly effective at minimizing the spread of influenza and reducing morbidity and mortality, social disruption and economic loss. Plans for future influenza epidemics and pandemics require national and international programs to be in place for the monitoring of influenza activity, the dissemination and exchange of information and the provision and delivery of sufficient quantities of vaccines and antiviral agents. This paper reviews and discusses the antigenic variations of the influenza virus, potential influenza pandemics, protective efficacy of inactivated vaccines and antiviral agents and preparation for control of future epidemics and pandemics.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Jason R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Po-Yen</ForeName>
<Initials>PY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cho</LastName>
<ForeName>Cheng T</ForeName>
<Initials>CT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chin</LastName>
<ForeName>Tom D Y</ForeName>
<Initials>TD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China (Republic : 1949- )</Country>
<MedlineTA>Kaohsiung J Med Sci</MedlineTA>
<NlmUniqueID>100960562</NlmUniqueID>
<ISSNLinking>1607-551X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>78</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12515400</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000341 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000341 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:12515400 |texte= Influenza: prospect for prevention and control. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12515400" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |